Base Therapeutics (Shanghai) is the lead sponsor of 4 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase EARLY_PHASE1. The drugs named most often in its trials are NK521 Cell. The most-studied condition is Hepatocellular Carcinoma (HCC).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT07561437 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: NK521 Cell |
Phase EARLY_PHASE1 | Recruiting | 2026-03 | China |
|
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962 · ClinicalTrials.gov ↗ · NSCLC
|
Phase EARLY_PHASE1 | Recruiting | 2023-07 | China |
|
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
Drug: NK521 Cell |
Phase EARLY_PHASE1 | Not yet open | 2026-06 | China |
|
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
NCT07166263 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Colorectal Cancer
|
Phase EARLY_PHASE1 | Not yet open | 2025-11 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Tongji Hospital | 6 |
| First Affiliated Hospital, Sun Yat-Sen University | 2 |
| Beijing Gene Key Life Technology | 2 |
| Broadenbio Ltd., Co | 1 |
| Xuhua Duan | 1 |
| Wang Xin | 1 |
| Singlera Genomics | 1 |
| GrandPharma (China) | 1 |
Sponsors with the most current trials registered for this condition.
Base Therapeutics (Shanghai) is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are NK521 Cell (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.